CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30+ lymphomas

Min Yu1,2,3, Longzi Liu4, Xiaoxi Zhou5

  • 1Jiangxi Provincial Key Laboratory of Hematological Diseases, Department of Hematology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwai Street, Nanchang, Jiangxi, 330006, P. R. China.

Abstract

No abstract available in PubMed .

Related Concept Videos